Intersections: HIV and COVID-19

  
Intersections #7: HIV and COVID-19 – COVID-19 and Children 

amfAR’s Dr. Rowena Johnston interviews Dr. Betsy Herold of Albert Einstein College of Medicine about her research on COVID-19 in children and in particular the mysterious multi-system syndrome that affects a small number of children, sometimes after they have cleared the virus.

Watch the full Intersections series here.

  
Intersections #6: HIV and COVID-19 – Tailoring Treatment  

Dr. Eileen Scully of Johns Hopkins University School of Medicine, a former amfAR grantee, talks to Dr. Rowena Johnston about the “moving target” of treatments for COVID-19 disease and what may be learned from the sex differences seen in the pandemic.

  
Intersections #5: HIV and COVID-19 – Antibody Testing, Treatment and Vaccines  

Dr. Michael Farzan of Scripps Research in Florida talks to Dr. Rowena Johnston about the potency and potential of antibodies, the foot soldiers of the immune system, for treating and preventing COVID-19.

  
Intersections #4: HIV and COVID-19 – Lessons from Australia 

Renowned Australian HIV researcher Professor Sharon Lewin speaks to amfAR’s Rowena Johnston about Australia’s response to the coronavirus and the collaboration among HIV researchers who are now addressing the new pandemic.

  
Intersections #3: HIV and COVID-19 - RNA Vaccine 

Professor Robin Shattock of Imperial College London talks to amfAR's Dr. Rowena Johnston about his team's efforts to rapidly develop and test a self-amplifying RNA vaccine against the coronavirus.
 

  
Intersections #2: HIV and COVID-19 - Testing 

In this interview, amfAR grantee Dr. Keith Jerome of the Fred Hutchinson Cancer Research Center discusses issues of testing for the novel coronavirus and his team’s early involvement in the development of such a test.
 

  
Intersections #1: HIV and COVID-19 - Hydroxychloroquine Trial  

amfAR’s Dr. Rowena Johnston talks to HIV researcher and amfAR grantee Dr. Timothy Schacker of the University of Minnesota about his involvement in clinical trials of experimental treatments for COVID-19.